Ensign Peak Advisors, Inc Allakos Inc. Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $53,848 - $103,986	10,600 Added 163.58%	17,080 $97,000
Q4 2021 Feb 11, 2022	SELL	$8.55 - $111.89 $145,418 - $1.9 Million	-17,008 Reduced 72.41%	6,480 $63,000
Q3 2021 Nov 12, 2021	BUY	$76.53 - $110.43 $571,526 - $824,691	7,468 Added 46.62%	23,488 $2.49 Million
Q1 2021 May 12, 2021	SELL	$109.73 - $153.66 $65,618 - $91,888	-598 Reduced 3.6%	16,020 $1.84 Million
Q4 2020 Feb 12, 2021	SELL	$79.58 - $152.45 $99,236 - $190,105	-1,247 Reduced 6.98%	16,618 $2.33 Million
Q3 2020 Nov 12, 2020	BUY	$66.43 - $90.99 $1.19 Million - $1.63 Million	17,865 New	17,865 $1.46 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.